[The absolute bioavailability of benzimidazole derivative RU-1205 in rats].
Pharmacokinetics of morpholinoethylimidazobenzimidazole derivative RU-1205 with kappa-agonist activity have been studied. The pharmacokinetic parameters were determined upon intravenous (10 mg/kg), peroral, and subcutaneous (50 mg/kg) administration. It is established that RU-1205 substance has high bioavailability (44.17 and 56.03% upon peroral and subcutaneous introduction, respectively).